# TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

> **NCT06106841** · PHASE1,PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 19 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** 400mg of TQB3909 tablets
- **DRUG:** 600mg of TQB3909 tablets

## Key facts

- **NCT ID:** NCT06106841
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-05
- **Primary completion:** 2024-10-16
- **Final completion:** 2024-10-16
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Study terminated for strategic business reasons
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06106841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06106841, "TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06106841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*